End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 43.55M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 88.66M | Net Debt 2020 | 874K 69.16M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Lois Chandler
COO | Chief Operating Officer | - | 30/06/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 21/05/20 |
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |